Tesamorelin Dosage: The Exact Beginner Protocol, Step by Step

Tesamorelin Dosage: The Exact Beginner Protocol, Step by Step

Most people who start tesamorelin get one instruction: "2mg, once a day." That's it. No mention of timing, food, injection site rotation, or the bloodwork that tells you if it's actually working, which is exactly how people waste months on a peptide that could be doing something useful.

Not medical advice: this article is educational only. Tesamorelin is FDA-approved (as Egrifta/Egrifta SV) specifically for reducing excess abdominal fat in people with HIV-associated lipodystrophy. Any other use, general fat loss, anti-aging, muscle building, is off-label and not something a physician has approved for the general public. Talk to a qualified healthcare provider before starting, adjusting, or stopping any peptide protocol.

---

Quick-Reference Summary

• Approved dose: 2mg subcutaneously, once daily, at bedtime
• Reconstitution: typically mixed with bacteriostatic water to a workable concentration (your vial's insert has exact ratios)
• Injection site: abdomen, rotated daily
• Best timing: empty stomach, 2+ hours after eating, right before sleep
• Bloodwork checkpoints: baseline IGF-1 and blood glucose, then rechecked around week 8-12
• Typical duration studied: 26-52 weeks in clinical trials, with reassessment built in
• Biggest beginner mistake: injecting right after a meal, which blunts the growth hormone response researchers actually measured

Who this is for: adults working with a clinician on a documented, approved use case, or researchers studying the compound under appropriate protocols. Who this is NOT for: anyone with active cancer, pregnant or breastfeeding people, or anyone hoping to self-treat a cosmetic goal without medical supervision, tesamorelin raises IGF-1 levels, and that needs monitoring.

---

What Tesamorelin Actually Does (So the Dosage Makes Sense)

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It doesn't add growth hormone to your body directly, it signals your pituitary gland to release more of its own [Source: PubMed]. That's an important distinction, because it means dosage decisions are less about "more equals more results" and more about working with your body's natural release pattern.

The clinical trials that got tesamorelin approved used 2mg once daily and measured visceral fat reduction over roughly 26 weeks, with IGF-1 levels tracked the entire time. That 2mg number isn't arbitrary, it's the dose that showed a measurable benefit without pushing IGF-1 into concerning territory for most trial participants. If you've seen protocols online suggesting higher doses "for faster results," that's not something the approved research supports, and we'd point you to why more isn't always better with tesamorelin dosing for the deeper dive on that specific myth.

---

The Step-by-Step Protocol

Step 1: Get baseline bloodwork before you inject anything

Before the first dose, a clinician should check IGF-1 and fasting blood glucose. This gives you a "before" number to compare against later, and it flags anyone who shouldn't be starting tesamorelin at all (active malignancy, uncontrolled diabetes, or a pituitary tumor, for example).

Step 2: Reconstitute correctly, and don't eyeball it

Tesamorelin ships as a lyophilized (freeze-dried) powder that has to be mixed with bacteriostatic water before injection. The ratio matters: too much water and you're under-dosing every shot; too little and you're overshooting. Follow the reconstitution instructions specific to your vial's labeled amount, and if you're unsure how this process works in general, our reconstitution walkthrough covers the math and technique. Using the right bacteriostatic water also matters more than people assume, it's what keeps the mixed solution stable between doses.

Step 3: Draw up 2mg, not "close enough"

Once reconstituted, the daily dose used in research is 2mg. Use an insulin syringe with clear markings and draw to the exact line every time. Eyeballing a dose "somewhere around there" is one of the most common reasons people report inconsistent results, because they're not actually giving themselves the same amount day to day.

Step 4: Inject into abdominal subcutaneous fat

Studies used subcutaneous (under the skin, not into muscle) injections in the abdomen. Pinch a fold of skin, insert the needle at roughly a 45-90 degree angle depending on your body fat, and inject slowly.

Step 5: Rotate your injection site every single day

This is the step most beginners skip, and it's the one that causes visible problems. Injecting the same quarter-inch of skin night after night can cause lipoatrophy (a dent or divot where fat tissue breaks down) or lipohypertrophy (a lumpy buildup). Move at least an inch or two from the previous night's spot, and rotate around the abdomen in a consistent pattern. Our injection site rotation guide has a simple map you can follow so you're not guessing.

Step 6: Time it right, empty stomach, right before bed

This is the detail almost every beginner protocol leaves out, and it's arguably the most important one. Growth hormone release naturally peaks during deep sleep, and eating, especially carbohydrates, spikes blood sugar in a way that can blunt the GHRH signal. The clinical trials dosed tesamorelin at bedtime on an empty stomach for this exact reason. Aim for at least 2 hours after your last meal.

Step 7: Store it correctly between doses

Reconstituted tesamorelin needs refrigeration and has a limited shelf life once mixed, typically used within a couple of weeks depending on the manufacturer's guidance. Leaving it at room temperature or in a hot car degrades the peptide faster than most people realize. Proper peptide storage is worth five extra minutes of reading if you're new to this.

Step 8: Recheck bloodwork around week 8-12

IGF-1 and glucose should be rechecked partway through, not just at the end. This is how a clinician catches an IGF-1 level climbing too high before it becomes a problem, rather than after.

Step 9: Reassess at the end of the studied window

Clinical trials ran their primary protocol for about 26 weeks before evaluating results, with some extension studies running longer. That's the window used to judge whether visceral fat measures actually changed, not two weeks, not a month. Set a real checkpoint with your clinician rather than deciding day-by-day whether it's "working."

---

How to Dose Tesamorelin the Right Way (Without Guessing)

If you take nothing else from this article, take this: the tesamorelin dosing protocol that produced measurable results in research was boring, consistent, and unglamorous. Same 2mg dose, same time of night, same empty stomach, tracked with bloodwork, not a rotating experiment of higher doses or shortened cycles chasing faster change. Consistency is the actual "hack" here, not dose escalation.

---

Common Mistakes That Waste a Dose (or Cause a Problem)

Mistake 1: Injecting right after dinner. Eating close to your dose blunts the growth hormone pulse the research was built around. If you eat late, push your injection back rather than doing it on a full stomach.

Mistake 2: Skipping site rotation. Divots and lumps under the skin aren't just cosmetic, they can also affect how consistently the peptide absorbs.

Mistake 3: Eyeballing reconstitution ratios. A slightly-off mix means every single dose afterward is wrong, not just one.

Mistake 4: No follow-up bloodwork. IGF-1 is the number that tells you whether tesamorelin is doing anything at all, and whether it's doing too much. Skipping it means dosing blind.

Mistake 5: Expecting visible changes in two weeks. The trials that established this dose measured change over roughly six months. Anyone promising fast results is not describing the research.

Mistake 6: Buying from an unverified source. Underdosed or contaminated product is a documented problem in the peptide space. A certificate of analysis isn't optional if you're serious about knowing what's actually in the vial.

Mistake 7: Stacking without understanding interactions. Adding other growth hormone secretagogues or peptides on top of tesamorelin without medical guidance increases the risk of pushing IGF-1 too high. If you're considering a stack, read about interactions between peptides before combining anything.

---

Red Flags: When to Stop and Call a Clinician

Stop and contact a healthcare provider if you notice any of the following:

• Swelling in the hands, feet, or face (fluid retention is a documented side effect tied to growth hormone pathway activity)
• New or worsening joint pain, especially in the hands or wrists, this can signal carpal tunnel-type symptoms sometimes reported with GH-axis compounds
• Signs of high blood sugar, excessive thirst, frequent urination, blurred vision
• Injection site reactions that don't resolve, persistent redness, warmth, or a hard lump that doesn't go away after a few days
• Any known or suspected active cancer diagnosis, growth hormone pathway activation is not appropriate to combine with active malignancy, and this should be ruled out before starting

None of these symptoms should be managed by adjusting your own dose. They're a reason to get bloodwork and a professional opinion, not a reason to push through.

---

Where This Fits With Other Fat-Loss Peptides

Tesamorelin's approved use is narrow, visceral fat reduction in a specific population, studied with a specific dosing protocol. If you're weighing it against broader weight-loss approaches like GLP-1 medications, the mechanisms aren't comparable, and it's worth understanding what tesamorelin actually does for fat loss before assuming it works like semaglutide or tirzepatide. It doesn't, and expecting GLP-1-level weight change from a GHRH analog is a setup for disappointment.

---

Medical Disclaimer

The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. This article shares published research and general educational information, not a personalized medical recommendation.

---

Sources

1. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance, Sports Medicine, 2026
2. Anti-Obesity Medications in Longevity and Aesthetic Medicine, Journal of Clinical Medicine, 2026
3. Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies, Clinics in Dermatology, 2026
4. U.S. Food and Drug Administration, Egrifta/Egrifta SV (tesamorelin) prescribing information, accessed via FDA.gov